Hematology/Oncology News

As former NCI Director W. Kimryn Rathmell, MD, PhD, MMHC, embarks on the next stage of her career as CEO of the James Cancer Hospital and Solove Research Institute at The Ohio State University, her goal remains the same — to make a difference.

A consensus statement published in Endocrine Practice examines how health care professionals should approach treating and screening people with tumors associated with multiple endocrine neoplasia type 1.

Monitoring blood levels of circulating tumor DNA in patients with stage 3 melanoma may accurately predict skin cancer recurrence, according to results from a phase 3 study published in The Lancet Oncology.

Select patients with breast cancer who experience pathologic complete response to neoadjuvant systemic therapy and undergo radiotherapy may be able to forego breast surgery, according to study results published in JAMA Oncology.

Zongertinib conferred benefit in certain patients with previously treated HER2-mutant advanced non-small cell lung cancer in a phase 1 trial, according to findings presented at American Association for Cancer Research Annual Meeting.

SAN DIEGO — Screening rates for colorectal cancers were doubled, CRC-related mortality cut in half and racial disparities nearly eliminated with a 20-year outreach program, according to study results presented at Digestive Disease Week.

In this edition, reduction efforts prevent 3.8 million lung cancer deaths since 1970, first-line combination should be ‘new standard’ in advanced lung cancer and more.

Smoking status added to the National Cancer Database for patients diagnosed with cancer in 2023 revealed variations in sociodemographic and socioeconomic factors, according to a research letter in JAMA Oncology.

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain patients with advanced head and neck squamous cell carcinoma, according to results of a randomized phase 3 study.